170 related articles for article (PubMed ID: 38171113)
1. Concentrations of S100B and neurofilament light chain in blood as biomarkers for checkpoint inhibitor-induced CNS inflammation.
Bjursten S; Zhao Z; Al Remawi H; Studahl M; Pandita A; Simrén J; Zetterberg H; Lundell AC; Rudin A; Ny L; Levin M
EBioMedicine; 2024 Feb; 100():104955. PubMed ID: 38171113
[TBL] [Abstract][Full Text] [Related]
2. Prognostic role of gamma-glutamyl transferase in metastatic melanoma patients treated with immune checkpoint inhibitors.
Winter J; Lenders MM; Gassenmaier M; Forschner A; Leiter U; Weide B; Purde MT; Flatz L; Cozzio A; Röcken M; Garbe C; Eigentler TK; Wagner NB
Cancer Immunol Immunother; 2021 Apr; 70(4):1089-1099. PubMed ID: 33113003
[TBL] [Abstract][Full Text] [Related]
3. Neuro-glial degeneration in Status Epilepticus: Exploring the role of serum levels of Neurofilament light chains and S100B as prognostic biomarkers for short-term functional outcome.
Giovannini G; Bedin R; Orlandi N; Turchi G; Cioclu MC; Biagioli N; Madrassi L; Pugnaghi M; Vaudano AE; Meletti S
Epilepsy Behav; 2023 Mar; 140():109131. PubMed ID: 36780777
[TBL] [Abstract][Full Text] [Related]
4. Histological diagnosis of immune checkpoint inhibitor induced acute renal injury in patients with metastatic melanoma: a retrospective case series report.
Hultin S; Nahar K; Menzies AM; Long GV; Fernando SL; Atkinson V; Cebon J; Wong MG
BMC Nephrol; 2020 Sep; 21(1):391. PubMed ID: 32894101
[TBL] [Abstract][Full Text] [Related]
5. Patients with chronic insomnia disorder have increased serum levels of neurofilaments, neuron-specific enolase and S100B: does organic brain damage exist?
Zhang P; Tan CW; Chen GH; Ge YJ; Xu J; Xia L; Wang F; Li XY; Kong XY
Sleep Med; 2018 Aug; 48():163-171. PubMed ID: 29957487
[TBL] [Abstract][Full Text] [Related]
6. Serum and cerebrospinal fluid brain damage markers neurofilament light and glial fibrillary acidic protein correlate with tick-borne encephalitis disease severity-a multicentre study on Lithuanian and Swedish patients.
Veje M; Griška V; Pakalnienė J; Mickienė A; Bremell D; Zetterberg H; Blennow K; Lindquist L; Studahl M
Eur J Neurol; 2023 Oct; 30(10):3182-3189. PubMed ID: 37431060
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan.
Kitagataya T; Suda G; Nagashima K; Katsurada T; Yamamoto K; Kimura M; Maehara O; Yamada R; Shigesawa T; Suzuki K; Nakamura A; Ohara M; Umemura M; Kawagishi N; Nakai M; Sho T; Natsuizaka M; Morikawa K; Ogawa K; Ohnishi S; Komatsu Y; Hata H; Takeuchi S; Abe T; Sakakibara-Konishi J; Teshima T; Homma A; Sakamoto N
J Gastroenterol Hepatol; 2020 Oct; 35(10):1782-1788. PubMed ID: 32187734
[TBL] [Abstract][Full Text] [Related]
8. Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune checkpoint inhibitor therapy: a single-centre analysis.
Verspohl SH; Holderried T; Behning C; Brossart P; Schäfer VS
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211006963. PubMed ID: 33912248
[TBL] [Abstract][Full Text] [Related]
9. C-reactive protein and immune-related adverse events as prognostic biomarkers in immune checkpoint inhibitor treated metastatic renal cell carcinoma patients.
Kankkunen E; Penttilä P; Peltola K; Bono P
Acta Oncol; 2022 Oct; 61(10):1240-1247. PubMed ID: 35905053
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory markers in autoimmunity induced by checkpoint inhibitors.
Husain B; Kirchberger MC; Erdmann M; Schüpferling S; Abolhassani AR; Fröhlich W; Berking C; Heinzerling L
J Cancer Res Clin Oncol; 2021 Jun; 147(6):1623-1630. PubMed ID: 33837821
[TBL] [Abstract][Full Text] [Related]
11. Serum levels of neurofilament light chain, neuron-specific enolase and S100 calcium-binding protein B during acute bacterial meningitis: a prospective cohort study.
Grønhøj MH; Sejbaek T; Hansen RW; Larsen L; Dahl M; Schierbeck J; Poulsen FR
Infect Dis (Lond); 2021 Jun; 53(6):409-419. PubMed ID: 33583314
[TBL] [Abstract][Full Text] [Related]
12. Immune-related adverse events correlate with improved survival in patients with advanced mucosal melanoma treated with nivolumab: A single-center retrospective study in Japan.
Otsuka M; Sugihara S; Mori S; Hamada K; Sasaki Y; Yoshikawa S; Kiyohara Y
J Dermatol; 2020 Apr; 47(4):356-362. PubMed ID: 31984569
[TBL] [Abstract][Full Text] [Related]
13. Quantitative imaging biomarkers of immune-related adverse events in immune-checkpoint blockade-treated metastatic melanoma patients: a pilot study.
Hribernik N; Huff DT; Studen A; Zevnik K; Klaneček Ž; Emamekhoo H; Škalic K; Jeraj R; Reberšek M
Eur J Nucl Med Mol Imaging; 2022 May; 49(6):1857-1869. PubMed ID: 34958422
[TBL] [Abstract][Full Text] [Related]
14. Salivary S100 calcium-binding protein beta (S100B) and neurofilament light (NfL) after acute exposure to repeated head impacts in collegiate water polo players.
Monroe DC; Thomas EA; Cecchi NJ; Granger DA; Hicks JW; Small SL
Sci Rep; 2022 Mar; 12(1):3439. PubMed ID: 35236877
[TBL] [Abstract][Full Text] [Related]
15. Temporal Trends and Outcomes Among Patients Admitted for Immune-Related Adverse Events: A Single-Center Retrospective Cohort Study from 2011 to 2018.
Molina GE; Zubiri L; Cohen JV; Durbin SM; Petrillo L; Allen IM; Murciano-Goroff YR; Dougan M; Thomas MF; Faje AT; Rengarajan M; Guidon AC; Chen ST; Okin D; Medoff BD; Nasrallah M; Kohler MJ; Schoenfeld SR; Karp Leaf RS; Sise ME; Neilan TG; Zlotoff DA; Farmer JR; Mooradian MJ; Bardia A; Mai M; Sullivan RJ; Semenov YR; Villani AC; Reynolds KL
Oncologist; 2021 Jun; 26(6):514-522. PubMed ID: 33655682
[TBL] [Abstract][Full Text] [Related]
16. Blood-based cerebral biomarkers in preeclampsia: Plasma concentrations of NfL, tau, S100B and NSE during pregnancy in women who later develop preeclampsia - A nested case control study.
Bergman L; Zetterberg H; Kaihola H; Hagberg H; Blennow K; Åkerud H
PLoS One; 2018; 13(5):e0196025. PubMed ID: 29719006
[TBL] [Abstract][Full Text] [Related]
17. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
Front Oncol; 2021; 11():749064. PubMed ID: 34900695
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Hematological Predictors of High-Grade Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors.
Manne A; Mulekar MS; Escobar DE; Alsayed A; Sharma G; Prodduturvar P; Khushman M; Howard JH; Gilbert R; Alkharabsheh O
J Clin Med Res; 2021 May; 13(5):268-275. PubMed ID: 34104278
[TBL] [Abstract][Full Text] [Related]
19. External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition.
Glehr G; Riquelme P; Yang Zhou J; Cordero L; Schilling HL; Kapinsky M; Schlitt HJ; Geissler EK; Burkhardt R; Schmidt B; Haferkamp S; Hutchinson JA; Kronenberg K
Front Immunol; 2022; 13():1011040. PubMed ID: 36248910
[TBL] [Abstract][Full Text] [Related]
20. Immune-related adverse events in cancer patients being treated with immune checkpoint inhibitors.
Byrne MM; Lucas M; Pai L; Breeze J; Parsons SK
Eur J Haematol; 2021 Dec; 107(6):650-657. PubMed ID: 34453348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
